›Portfolio Companies

Past, Present and Future Leaders

The managing directors of IWHP are proud and privileged to have partnered with visionary management teams who are shaping the future of Biotech, Medical Devices and Healthcare IT. The groundbreaking businesses they have created are representative of the industry-leading companies that InterWest has helped build over the last three decades.

Our Companies

VENTURE INVESTING IN BREAKTHROUGH HEALTHCARE COMPANIES

Farah Champsi

Farah Chapmsi

farahchampsi

Managing Director

"This is a great time to build a company with breakthrough science and disease-modifying pharmaceuticals. I am excited to help visionary management teams execute their goals and build sustainable companies that will improve patients' lives. "

InterWest Team

Current Investments

Prior Investments

Farah's bio

Portfolio
Company News

Farah's
Perspective

Farah's Buzz

Farah's video

Farah Champsi joined InterWest Partners as a managing director in May 2015. Since 2000, she has been a managing director at Alta Partners and played a key role in raising and managing over $1 billion in life sciences venture funds. She currently serves on the boards of Allakos and Kite Pharma. Farah is also responsible for Alta's investments in Cytokinetics, Intarcia, and Trevena. Previously, she led Alta's investments in Agensys (acquired by Astellas), Esperion (acquired by Pfizer), Excaliard (acquired by Pfizer), Orphan Medical (acquired by Jazz), Chimerix (IPO) and Portola (IPO). 

Prior to joining Alta in 2000, Farah was an investment banker for 13 years at Robertson Stephens & Company, where she focused on biotechnology and other life sciences companies. She was elected head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street.

Farah received an M.B.A. from Stanford University and a B.A. in Economics from Smith College. She serves on the board of UCSF Benioff Children’s Hospitals.

When I began my career in biotech as an investment banker at Robertson Stephens in 1987 there were only a few dozen biotech companies. Today there are over a thousand companies. The biotech industry is undergoing unprecedented growth based on the success of numerous blockbuster products. This is a great time to build a company with breakthrough science and disease-modifying pharmaceuticals. I am excited to help visionary management teams execute their goals and build sustainable companies that will improve patients' lives.
Farah Chapmsi